Plain-English translation of NCT07136389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing two experimental medications called and for people with systemic lupus erythematosus (SLE) who have active skin disease. The trial will evaluate how safe these medications are, how your body processes them, and how well they work — testing them individually and in combination. Researchers will closely monitor participants to understand the best doses and whether this approach helps control lupus-related skin symptoms.
Current treatments for lupus skin disease don't work well enough for everyone, and some people experience side effects or don't respond adequately to standard care. This trial is designed to see if this new treatment approach offers a safer and more effective option for people whose skin disease remains active despite existing medications.
You likely qualify if…
You likely don't qualify if…
The trial has two stages. In Stage 1, small groups of participants receive increasing doses of one or both medications intravenously (through an IV), with safety monitoring and at least 2 weeks between dose increases. After 12 weeks, researchers review safety data before moving forward. Stage 2 involves new participants receiving the two medications in combination at different dose levels, also monitored carefully over 12 weeks. Throughout, you'll have regular clinic visits, blood tests, and skin assessments to monitor how the treatment is working and any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Russia